MERCK
20.12.2021 14:02:06 CET | Business Wire | Press release
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.
“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.
Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.
Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.
About Chord Therapeutics
Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. Chord is advancing its lead drug candidate, CRD1 (cladribine), for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and generalized myasthenia gravis (gMG). Chord Therapeutics was founded in 2014 and launched in October 2020 with Series A funding by its sole investor, Omega Funds, a leading international venture capital firm focused on delivering impactful medicines to patients.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bentley Systems Announces 2026 Year in Infrastructure Event and YII Awards Honoring the World’s Most Innovative Use of Infrastructure Engineering Software18.3.2026 13:00:00 CET | Press release
Awards build on a two-decade legacy of recognized innovation, setting the benchmark for excellence across the world’s most critical infrastructure assetsCall for nominations now open; submissions will be accepted through May 3, 2026 Bentley Systems, Incorporated (NASDAQ: BSY), the infrastructure engineering software company, today announced the opening of submissions for the Year in Infrastructure event and YII Awards program, which recognizes digital innovation in how infrastructure is designed, built, and operated using Bentley software. Submissions will be accepted through May 3, at 11:59 p.m. EDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318559906/en/ Bentley Systems announced the opening of submissions for the Year in Infrastructure event and YII Awards program, which recognizes digital innovation in how infrastructure is designed, built, and operated using Bentley software. Submissions will be accepted through
Veracode Expands Industry-Leading Fix with AI-Powered SCA Remediation to Combat Software Supply Chain Risk18.3.2026 13:00:00 CET | Press release
New Capability Automates Open-Source Vulnerability Remediation as Software Supply Chain Attacks Surge RSA Conference (booth #435)--Veracode, the global leader in application risk management, today announced Veracode Fix for Software Composition Analysis (SCA), an AI-powered solution to address software supply chain risk. The enhanced automated remediation engine—the next evolution of Veracode’s industry-leading Fix solution—enables organizations to detect and remediate open-source vulnerabilities easily, before code reaches production. Designed to integrate seamlessly into existing developer workflows, it delivers third-party updates and first-party code refactoring without breaking builds or disrupting development. In 2025, software supply chain breaches accounted for 30 percent of external attacks. Meanwhile Veracode’s 2026 State of Software Security (SoSS) Report revealed 82 percent of organizations struggle with escalating security debt, largely due to open-source dependencies. Ver
Armis Appoints Simon Mouyal as Chief Marketing Officer18.3.2026 13:00:00 CET | Press release
Strategic marketing executive to accelerate adoption of Armis Centrix™ in the agentic AI era and extend the company’s category leadership in cyber exposure management and CPS security Armis, the cyber exposure management & security company, today announced the appointment of Simon Mouyal as Chief Marketing Officer. In this role, Mouyal will oversee Armis’ global marketing strategy and execution to accelerate category leadership and demand for Armis Centrix™, the Armis Cyber Exposure Management Platform. During the next phase of Armis’ expansion, he will scale the global marketing organization and help further drive the company’s rapid growth and market penetration. “As we enter our next chapter of hyper-growth, I'm thrilled to have Simon joining our leadership team,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Simon will be instrumental in modernizing our global marketing engine and solidifying Armis as the definitive leader in cyber exposure management. He's a category creator
Americhem Appoints Kilian Lamprecht as Vice President of Mergers & Acquisitions to Accelerate Strategic Growth18.3.2026 12:00:00 CET | Press release
Americhem, a global leader in polymer solutions, today announced that Kilian Lamprecht has joined the company as Vice President of Mergers & Acquisitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317304976/en/ Kilian Lamprecht, Vice President of Mergers & Acquisitions, Americhem Lamprecht brings extensive experience in corporate development and integration within global industrial and technology organizations. He will work closely with Americhem’s executive leadership team and investment partner PPC to identify and execute strategic acquisitions, partnerships and portfolio investments that expand the company’s capabilities, product portfolio and geographic reach. “Americhem has a long history of disciplined growth and innovation in materials science,” said John Richard, CEO of Americhem. “With the support of PPC, we are expanding our ability to pursue strategic acquisitions that strengthen our technology platform, b
Reply Announces a Partnership With Mistral AI to Develop Sovereign and Enterprise-grade Artificial Intelligence Solutions18.3.2026 09:00:00 CET | Press release
Reply [EXM, STAR: REY] today announced a new partnership agreementwithAI leader Mistral AI aimed at accelerating the adoption of local, customisable, secure and enterprise-grade generative AI solutions at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318232777/en/ Through this collaboration, Reply and Mistral AI provide a trusted and secure environment on European infrastructures, accelerating the adoption of advanced AI solutions while enabling organizations with stringent regulatory, privacy and data protection requirements to fully leverage generative AI. At the core of the collaboration is a shared vision of frontier AI, designed to enable organizations to adopt AI solutions while ensuring data control, protection of sensitive information, compliance with regulatory requirements and deployment on European infrastructures. By combining Mistral AI’s high-performance AI models with Reply’s expertise in designing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom